BNP (B-type Natriuretic Peptide) vs IGF-1 LR3
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →IGF-1 LR3
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | IGF-1 LR3 |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 20 mcg–100 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 4–6 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Binds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Research protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Intramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Hypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), IGF-1 LR3 are both commonly used for:
Key Differences
Unique to IGF-1 LR3:
Which Has Stronger Evidence?
| Goal | BNP (B-type Natriuretic Peptide) | IGF-1 LR3 |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
IGF-1 LR3
- IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep.
American journal of physiology. Endocrinology and metabolism, 2025
- Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration.
International journal of biological macromolecules, 2025
- Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.
Journal of developmental origins of health and disease, 2023
Ready to Learn More?
Looking for trusted sources?